Clostridium Difficile Clinical Trials 2024

Clostridium Difficile Clinical Trials 2024

Clostridium Difficile research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in clostridium difficile clinical trials today.

Clostridium Difficile Clinical Trials

Here are the 5 most popular medical studies for clostridium difficile

Popular filter options for clostridium difficile trials

C. Diff Clinical Trials

View 11 C. diff medical studies.

CDI Clinical Trials

View 6 CDI medical studies.

Clostridium Difficile Clinical Trials With No Placebo

View 18 clostridium difficile medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to clostridium difficile

What are the top hospitals conducting clostridium difficile research?

Clostridium difficile, commonly known as C. difficile, is a formidable bacterium that causes severe gastrointestinal infections. While its prevalence can be concerning, there are hospitals at the forefront of tackling this infectious disease through clinical trials. In Hines, Illinois, the Edward Hines Jr. VA Hospital is actively engaged in two ongoing trials dedicated to understanding and combating C. difficile infections. Similarly, the VA Portland Health Care System in Oregon and Clement J. Zablocki VA Medical Center in Milwaukee have also prioritized this battle with two active clostridium difficile trials each.

In Philadelphia's Children's Hospital and the University of Pittsburgh Medical Center (UPMC), world-renowned institutions are joining forces to unravel the mysteries surrounding this challenging infection through their respective two and one active clostridium difficile trials.

It may come as a surprise that despite being such critical healthcare providers, none of these top hospitals has previously conducted any specific clinical trial solely focused on combatting C.difficile before now; however their current dedication shows promising progress towards gaining further insights into effective prevention and treatment options for patients affected by it.

While Clostridium difficile can cause debilitating symptoms and pose risks to vulnerable populations such as children or veterans who rely on specialized medical care offered by these distinguished facilities - but thanks to these hospitals' relentless pursuit of innovative solutions even for niche conditions like C.difficle; we might soon witness significant breakthroughs which will ultimately benefit not only those directly impacted but also contribute towards global health improvements initiatives

Which are the best cities for clostridium difficile clinical trials?

Calgary, Alberta; Milwaukee, Wisconsin; Durham, North carolina; Philadelphia, Pennsylvania; and Baltimore, Maryland are the top cities for clostridium difficile (CDI) clinical trials. Each city has 3 active trials focusing on different aspects of CDI treatment and prevention. From testing the efficacy of RBX2660 to studying the impact of universal gloving and investigating alternative treatments like Fidaxomicin, these clinical trials aim to advance our understanding of CDI management and develop better strategies for combating this challenging infection.

Which are the top treatments for clostridium difficile being explored in clinical trials?

Clinical trials are shedding light on the top treatments for Clostridium difficile, a challenging infection to tackle. Among the leading contenders in these trials are:

  • Fecal microbiota transplantation (FMT)
  • Bezlotoxumab

FMT is gaining traction as a potential game-changer, with its ability to restore healthy gut bacteria and combat C. difficile infections. Meanwhile, bezlotoxumab is showing promise as a monoclonal antibody that can prevent recurrent infections by targeting toxins produced by C. difficile. These innovative approaches hold significant hope for patients battling this persistent infection.

What are the most recent clinical trials for clostridium difficile?

Exciting developments in the field of clostridium difficile research offer hope for improved management and treatment strategies. One recent clinical trial investigated the efficacy of chlorhexidine, a powerful antiseptic agent, in combating clostridium difficile infections. Another study explored an extended vancomycin regimen as an intervention method against this challenging infection. These trials provide valuable insights into potential approaches for addressing clostridium difficile, offering promising avenues to enhance patient outcomes and reduce the burden of this disease.

What clostridium difficile clinical trials were recently completed?

Recently completed clinical trials for Clostridium difficile, a bacterium that can cause severe gastrointestinal infections, have yielded valuable insights. One such study involved the investigation of Uproleselan as a potential treatment option for this challenging infection. Additionally, researchers evaluated the efficacy and safety of mRNA-1273 in combating Clostridium difficile infections. These groundbreaking advancements underline the dedication of researchers in their pursuit to combat this persistent bacterium and offer hope for those affected by its debilitating effects.